Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Liraglutide Alters Bone Marrow Exosome-Mediated miRNA Signal Pathways in Ovariectomized Rats with Type 2 Diabetes

Medical Science Monitor ◽

10.12659/msm.906603 ◽

2017 ◽

Vol 23 ◽

pp. 5410-5419 ◽

Cited By ~ 11

Author(s):

Jin Li ◽

Ling-Zhi Fu ◽

Lu Liu ◽

Fen Xie ◽

Ru-Chun Dai

Keyword(s):

Type 2 Diabetes ◽

Bone Marrow ◽

Receptor Agonist ◽

Ovariectomized Rats ◽

Signal Pathways ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

Download Full-text

Combination of Premixed Insulin with Glucagon-Like Peptide-1 Receptor Agonist (GLP-1) for Uncontrolled Type 2 Diabetes Mellitus (T2DM) Patients

Diabetes ◽

10.2337/db18-2231-pub ◽

2018 ◽

Vol 67 (Supplement 1) ◽

pp. 2231-PUB

Author(s):

SASAN FAZELI ◽

NICOLE EHRHARDT

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Receptor Agonist ◽

Premixed Insulin ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

Download Full-text

938-P: The Relationship between Timing of Initiation on a Glucagon-Like Peptide-1 Receptor Agonist and HbA1c among Patients with Type 2 Diabetes

Diabetes ◽

10.2337/db20-938-p ◽

2020 ◽

Vol 69 (Supplement 1) ◽

pp. 938-P

Author(s):

RALEIGH E. MALIK ◽

REEMA MODY ◽

MAUREEN J. LAGE ◽

KRISTINA BOYE

Keyword(s):

Type 2 Diabetes ◽

Receptor Agonist ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1 ◽

Timing Of Initiation ◽

The Relationship

Download Full-text

Glucagon-Like Peptide 1 Receptor Agonist (GLP1RA) Exposure and Outcomes in Type 2 Diabetes: A Systematic Review of Population-Based Observational Studies

Diabetes Therapy ◽

10.1007/s13300-021-01021-1 ◽

2021 ◽

Author(s):

Thomas M. Caparrotta ◽

Jack B. Templeton ◽

Thomas A. Clay ◽

Sarah H. Wild ◽

Rebecca M. Reynolds ◽

...

Keyword(s):

Systematic Review ◽

Type 2 Diabetes ◽

Observational Studies ◽

Receptor Agonist ◽

Population Based ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

Download Full-text

Insulin/Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy for the Treatment of Type 2 Diabetes: Are Two Agents Better Than One?

Clinical Diabetes ◽

10.2337/cd17-0065 ◽

2018 ◽

Vol 36 (2) ◽

pp. 138-147 ◽

Cited By ~ 4

Author(s):

Vanita R. Aroda ◽

Joseph R. Arulandu ◽

Anthony J. Cannon

Keyword(s):

Type 2 Diabetes ◽

Combination Therapy ◽

Receptor Agonist ◽

Two Agents ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1 ◽

Better Than

Download Full-text

4324Effects of the glucagon like peptide-1 receptor agonist on arterial stiffness, LV myocardial deformation and oxidative stress in newly diagnosed type 2 diabetes after 6-month treatment

European Heart Journal ◽

10.1093/eurheartj/ehy563.4324 ◽

2018 ◽

Vol 39 (suppl_1) ◽

Author(s):

I Ikonomidis ◽

G Pavlidis ◽

V Lambadiari ◽

F Kousathana ◽

H Triantafyllidi ◽

...

Keyword(s):

Oxidative Stress ◽

Type 2 Diabetes ◽

Arterial Stiffness ◽

Receptor Agonist ◽

Myocardial Deformation ◽

Newly Diagnosed ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1 ◽

And Oxidative Stress

Download Full-text

The good companions: insulin and glucagon-like peptide-1 receptor agonist in type 2 diabetes. A systematic review and meta-analysis of randomized controlled trials

Diabetes Research and Clinical Practice ◽

10.1016/j.diabres.2019.06.009 ◽

2019 ◽

Vol 154 ◽

pp. 101-115 ◽

Cited By ~ 5

Author(s):

Maria Ida Maiorino ◽

Paolo Chiodini ◽

Giuseppe Bellastella ◽

Lorenzo Scappaticcio ◽

Miriam Longo ◽

...

Keyword(s):

Systematic Review ◽

Type 2 Diabetes ◽

Randomized Controlled Trials ◽

Receptor Agonist ◽

Meta Analysis ◽

Controlled Trials ◽

Randomized Controlled ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

Download Full-text

Effects of 6 months glucagon-like peptide-1 receptor agonist treatment on endothelial function in type 2 diabetes mellitus patients

Diabetes Obesity and Metabolism ◽

10.1111/dom.12089 ◽

2013 ◽

Vol 15 (8) ◽

pp. 770-773 ◽

Cited By ~ 23

Author(s):

N. D. Hopkins ◽

D. J. Cuthbertson ◽

G. J. Kemp ◽

C. Pugh ◽

D. J. Green ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Endothelial Function ◽

Receptor Agonist ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

Download Full-text

Review for "The impact of the Glucagon-Like Peptide-1 Receptor Agonist Liraglutide on Natriuretic Peptides in Heart Failure Patients with Reduced Ejection Fraction with and without Type 2 Diabetes"

10.1111/dom.14135/v2/review2 ◽

2020 ◽

Keyword(s):

Heart Failure ◽

Type 2 Diabetes ◽

Ejection Fraction ◽

Receptor Agonist ◽

Reduced Ejection Fraction ◽

Heart Failure Patients ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1 ◽

The Impact

Download Full-text

Review for "The impact of the Glucagon-Like Peptide-1 Receptor Agonist Liraglutide on Natriuretic Peptides in Heart Failure Patients with Reduced Ejection Fraction with and without Type 2 Diabetes"

10.1111/dom.14135/v1/review4 ◽

2020 ◽

Keyword(s):

Heart Failure ◽

Type 2 Diabetes ◽

Ejection Fraction ◽

Receptor Agonist ◽

Reduced Ejection Fraction ◽

Heart Failure Patients ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1 ◽

The Impact

Download Full-text

Review for "The impact of the Glucagon-Like Peptide-1 Receptor Agonist Liraglutide on Natriuretic Peptides in Heart Failure Patients with Reduced Ejection Fraction with and without Type 2 Diabetes"

10.1111/dom.14135/v1/review3 ◽

2020 ◽

Keyword(s):

Heart Failure ◽

Type 2 Diabetes ◽

Ejection Fraction ◽

Receptor Agonist ◽

Reduced Ejection Fraction ◽

Heart Failure Patients ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1 ◽

The Impact

Download Full-text